Simeox: for a better quality of life
Innovate to improve the day-to-day life of patients suffering from respiratory diseases
Bronchial clearance of patients with cystic fibrosis is an essential component of the fight to preserve lung function1. Chronic coughing and mucus production in COPD patients are very closely associated with the occurrence of exacerbations2.
Shortness of breath, fatigue, excessive coughing, and an abundant, difficult-to-mobilize mucus significantly affect the day-to-day life of patients with chronic lung diseases. In addition, clearing the airways of those patients is challenging due to their dyspnea, fatigability, level of distension and anxiety.
It is with these challenges in mind that PhysioAssist has innovated and developed the Simeox technology. The objective was to find a solution for patients which allows them to preserve their lung function, relieve their symptoms and thus improve their quality of life.
Several years of pure research in partnership with the CNRS and Inserm
Simeox is the result of several years of research and development in partnership with the CNRS (National Center for Scientific Research), Inserm (French National Institute of Health & Medical Research) and prestigious university hospitals.
The PhysioAssist research program has been dedicated to studying bronchial mucus and has led to the development of the technology present in Simeox 3, 4.
1 Lester et al. Airway-Clearance Therapy Guidelines and Implementation. Respir Care 2009;54(6):733 750. 2 Burgel et al. Cough and Sputum Production Are Associated With Frequent Exacerbations and Hospitalizations in COPD Subjects. Chest 2009 ; 135 : 975-982. 3 Lafforgue et al. Thermo-physical properties of synthetic mucu s for the study of airway clearance. J Biomed Mater Res Part A 2017:105A:3025 3033. 4 Lafforgue et al. Rheological properties of synthetic mucus for airway clearance. J Biomed Mater Res Part A 2017:00A:000 000. 5 Benefits of Simeox airway clearance technology in non-CF patients with bronchiectasis, Iwan et al., ERJ September 2018, 52 (Supplement 62). 6 Effects of a new Airway Clearance Technology versus manual physiotherapy in COPD, Mihaltan et al., ERJ September 2018, 52 (Supplement 62). 7 Rapport de l étude clinique SIMETOL, Février 2019. 8 Revue des Maladies Respiratoires, Volume 36, Supplément, 2019.
Clinical results
Improvement of lung function characteristics such as FEV1 and FVC 5, 6
Improvement of the quality of life in COPD and Bronchiectasis as assessed by the CAT score 5, 6
Improvement of exercise capacity in Bronchiectasis as assessed by 6MWT 5
Improved symptoms 5, 6 and secretion clearance 7, 8
High subjective effectiveness in Simeox performance vs. conventional physiotherapy 7, 8
